Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches.
In type II diabetes mellitus the activity of the endogenous fibrinolytic system is reduced secondary to increased plasma activity of the plasminogen activator inhibitor type 1 (PAI-1). Because PAI-1 is considered an independent risk factor for cardiovascular disease, increased PAI-1 activity in diabetes mellitus may partly explain the increased susceptibility to both primary atherosclerosis and restenosis after angioplasty in this disease. The factors contributing to increased PAI-1 expression in diabetes mellitus are reviewed as well as possible therapeutic approaches to normalize increased PAI-1 expression.
Nordt
T K
TK
Department of Cardiology, University of Freiburg, Germany. nordt@mm31.ukl.uni-freiburg.de
Bode
C
C
D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000009:adverse effects / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1